Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03881761
Recruitment Status : Recruiting
First Posted : March 19, 2019
Last Update Posted : March 21, 2019
Sponsor:
Collaborator:
Henan Hualong Biotechnology Company
Information provided by (Responsible Party):
Henan Cancer Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : January 31, 2021
  Estimated Study Completion Date : January 31, 2022